Scientific Advisory Council discusses future of cell and gene therapy research funding.
Michael T. Lotze, MD
Christine Brown, PhD
E. Antonio Chiocca, MD, PhD
Alliance for Cancer Gene Therapy’s revered Scientific Advisory Council (SAC) held its annual meeting on January 28, 2022. SAC members discussed the past, present and future of cancer cell and gene therapy, including the best ways for the Alliance to leverage its fundraising efforts to advance the very best research in the field.
The SAC, along with ACGT board members and Fellows, heard presentations on CAR T-cell therapy for pediatric cancers and glioblastoma from Drs. Crystal Mackall (Stanford University) and Christine Brown (City of Hope), an update on ACGT-funded research into targeting macrophages for lung and ovarian cancer from Dr. Brian Brown (Mount Sinai) and held a robust discussion on the pros and cons of autologous and allogeneic product development led by Dr. Carl June (University of Pennsylvania) and Chen Schor (ACGT board member and CEO of Adicet Bio).
This is the first therapy approved for uveal melanoma and the first engineered T-cell receptor approved by the FDA for any type of malignancy.
Alliance for Cancer Gene Therapy has an explanation of how T-cell receptor therapy works, along with why this type of cell and gene therapy might be more effective than CAR T-cell therapies at treating solid tumors, like glioblastoma and pancreatic cancer.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.